NCT07518446 Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)
| NCT ID | NCT07518446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amager Hospital |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,800 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,800 participants in total. It began in 2024-09-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of Denmark to improve the detection and follow-up of somatic disease among patients with psychotic and affective disorders. This study evaluates whether integrating structured somatic screening into mental health services leads to improved identification and management of somatic disease compared with care as usual. Using a quasi-experimental controlled design with a matched cohort, outcomes among patients exposed to the SomaScreen intervention are compared with those of patients receiving usual care in comparable psychiatric outpatient clinics outside the Capital Region.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older. * Referred to FACT or OPUS psychiatric outpatient clinics in the Capital Region of Denmark. * Starting a new outpatient treatment episode in FACT or OPUS. * Diagnosed with psychotic or affective disorders (ICD-10 F20-F39), including those with comorbid substance use disorders (F10-F19). Exclusion Criteria: * Individuals younger than 18 years. * Patients in geriatric outpatient clinics. * Individuals not in the target diagnosis group (i.e., without psychotic or affective disorders, F20-F39). * Individuals who do not meet the inclusion criteria above.
Contact & Investigator
Lene F Eplov, MD, PhD, Associate Professor
PRINCIPAL INVESTIGATOR
Amager Hospital
Frequently Asked Questions
Who can join the NCT07518446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07518446 currently recruiting?
Yes, NCT07518446 is actively recruiting participants. Contact the research team at Lene.Falgaard.Eplov@regionh.dk for enrollment information.
Where is the NCT07518446 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07518446 clinical trial?
NCT07518446 is sponsored by Amager Hospital. The principal investigator is Lene F Eplov, MD, PhD, Associate Professor at Amager Hospital. The trial plans to enroll 2,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.